Zydus Lifesciences Secures USFDA Approval for Ascorbic Acid Injection

USD 11.6 million U.S. market opportunity for reference brand.
180-day Competitive Generic Therapy (CGT) marketing exclusivity.

Reader Takeaway: USFDA approval with exclusivity is a positive operational development for the company's U.S. market expansion.

What just happened

Zydus Lifesciences announced it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ascorbic Acid Injection USP. The approval covers dosages of 25,000 mg/50 mL (500 mg/mL) and 5,000 mg/10 mL (500 mg/mL).

This product is a generic equivalent to the reference listed drug, Ascor® Injection. A significant aspect of this approval is the designation as a Competitive Generic Therapy (CGT) by the USFDA.

Why this matters

Receiving Competitive Generic Therapy (CGT) designation grants Zydus Lifesciences a 180-day marketing exclusivity in the U.S. market. This exclusivity period begins from the first day of commercial marketing and provides a competitive advantage, allowing the company to capture market share without immediate generic competition.

This approval contributes to the strengthening of Zydus Lifesciences' existing U.S. generics portfolio, particularly in the injectable segment.

The backstory

The Ascorbic Acid Injection USP is indicated for the short-term treatment of scurvy in adult and pediatric patients aged 5 months and older. It is specifically for cases where oral administration is not feasible, insufficient, or contraindicated.

As of June 30, 2026, Zydus Lifesciences has a strong track record with the USFDA, accumulating 448 approvals and filing a total of 513 ANDAs, demonstrating its consistent efforts in expanding its generic drug offerings.

What changes now

With the final USFDA approval and CGT exclusivity, Zydus Lifesciences can now plan its commercial launch strategy for Ascorbic Acid Injection USP in the U.S. market. The company will aim to leverage the 180-day exclusivity period to establish a market presence.

Risks to watch

While the CGT exclusivity is a significant advantage, the market opportunity for the reference brand is modest at approximately USD 11.6 million annually (based on IQVIA MAT June 2026 data). Sustained growth will depend on Zydus's ability to expand its product range and capture market share beyond this initial exclusivity period.

Peer comparison

Zydus Lifesciences is a significant player in the U.S. generics market, with a substantial number of ANDA approvals. This latest approval aligns with its strategy of expanding its generics portfolio. Other major Indian pharmaceutical companies also actively pursue USFDA approvals for generic drugs, contributing to a competitive landscape.

Context metrics (time-bound)

According to IQVIA MAT data for June 2026, the U.S. market for the reference brand of Ascorbic Acid Injection reported annual sales of approximately USD 11.6 million.

As of June 30, 2026, Zydus Lifesciences had accumulated 448 approvals from the USFDA and filed 513 ANDAs.

What to track next

Investors will be keen to track the commercial launch date of the Ascorbic Acid Injection USP and the sales performance during the 180-day exclusivity period. Monitoring future ANDA filings and approvals from Zydus Lifesciences will also be important.